key: cord-0732972-wz1jv221
authors: Asadi‐Pooya, Ali A.; Akbari, Ali; Emami, Amir; Lotfi, Mehrzad; Rostamihosseinkhani, Mahtab; Nemati, Hamid; Barzegar, Zohreh; Kabiri, Maryam; Zeraatpisheh, Zahra; Farjoud‐Kouhanjani, Mohsen; Jafari, Anahita; Sasannia, Fateme; Ashrafi, Shayan; Nazeri, Masoume; Nasiri, Sara; Shahisavandi, Mina
title: Long COVID syndrome‐associated brain fog
date: 2021-10-24
journal: J Med Virol
DOI: 10.1002/jmv.27404
sha: 147da010d6a75c2f347e2be55d75460169779131
doc_id: 732972
cord_uid: wz1jv221

We investigated the frequency of brain fog in a large cohort of patients with documented coronavirus disease‐2019 (COVID‐19) who have survived the illness. We also scrutinized the potential risk factors associated with the development of brain fog. Adult patients (18–55 years of age), who were referred to the healthcare facilities anywhere in Fars province from February 19, 2020 to November 20, 2020 were included. All patients had a confirmed COVID‐19 diagnosis. In a phone call, at least 3 months after their discharge from the hospital, we obtained their current information. A questionnaire was specifically designed for data collection. In total, 2696 patients had the inclusion criteria; 1680 (62.3%) people reported long COVID syndrome (LCS). LCS‐associated brain fog was reported by 194 (7.2%) patients. Female sex (odds ratio [OR]: 1.4), respiratory problems at the onset (OR: 1.9), and intensive care unit (ICU) admission (OR: 1.7) were significantly associated with reporting chronic post‐COVID “brain fog” by the patients. In this large population‐based study, we report that chronic post‐COVID “brain fog” has significant associations with sex (female), respiratory symptoms at the onset, and the severity of the illness (ICU admission).

It has been more than 18 months since the start of the coronavirus disease-2019 (COVID- 19) pandemic. While during the early stages of the pandemic people were largely concerned by its risk of death and later on everybody recognized the psychosocial consequences of the pandemic, recently, the postacute phase lingering symptoms of the disease has attracted attention. 1 Many people, who survived the COVID-19, have reported a variety of persistent signs and symptoms after the acute phase of the disease. 2 The National Institute for Health and Clinical Excellence, the Scottish Intercollegiate Guidelines Network, and the Royal College of General Practitioners have jointly developed the following definition for the post-COVID syndrome: "signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks, and are not explained by an alternative diagnosis." 3 Some other experts have considered the persistence of symptoms (e.g., fatigue, memory problems, breathlessness, muscle pain that could not be attributed to any other cause) beyond 2 weeks for mild disease, beyond 4 weeks for moderate to severe illness, and beyond 6 weeks for critically ill patients as "long COVID syndrome" (LCS). 4 COVID-19 may damage the brain in various ways; encephalitis and cerebrovascular accidents have been reported in the literature before. 5 However, other long-term effects of the COVID-19 on the brain may be subtler; persistent impairment in sustained attention or cognition are two examples. [6] [7] [8] Brain fog is a general term used to describe the feeling of being mentally slow, fuzzy, or spaced out. 9 It affects one's ability to think or concentrate. 10 As physicians, we have been hearing from many survivors of COVID-19 who are complaining of "brain fog" after recovering from the illness.

In the current study, we investigated the frequency of LCSassociated brain fog in patients who have survived the COVID-19.

Also, we scrutinized the potential risk factors associated with the development of brain fog in a large cohort of patients with documented COVID-19 to add to the existing literature.

In this study, all consecutive adult patients (18-55 years of age) who were referred to and admitted at healthcare facilities (55 centers) anywhere in Fars province (located in the south of Iran with a population of 4 851 000 people) from February 19, 2020 (the start date of the pandemic in Iran) 11 to November 20, 2020 were included.

All patients had a confirmed COVID-19 diagnosis by a positive result on real-time polymerase chain reaction (PCR) testing of nasopharyngeal and oropharyngeal samples.

For all patients, the following data were collected at the emergency room by the admitting physician: sex, age, presence of fever, respiratory distress, muscle pain, cough, change in mental status, loss of smell, dizziness, headache, nausea, vomiting, abdominal pain, and anorexia. Other collected data included: Real-time PCR test results and admission to a hospital ward (i.e., COVID-specific ward, intensive care unit [ICU], or others). Underlying chronic health problems were also collected (self-declared) (i.e., liver, cardiac, renal, or neurological, and also diabetes mellitus [DM] , cancer, hypertension [HTN], pulmonary disorders). No data were available about the hospital course of the patients (e.g., laboratory test results, management, complications). However, the outcome was also recorded in the database, as dead or discharged.

In a phone call to the discharged patients (survivors) (made by the last 12 authors), at least 3 months after their acute illness (from 1 to 14 March 2021), we investigated their current health status and obtained their information if they agreed to participate and answer the questions (consented orally-Supporting Information Appendix S1). We randomly selected every other adult patient in our database (sorted by their phone numbers). If someone did not answer, we selected the previous patient in the list (who was skipped initially) ( Figure 1 ).

A questionnaire (Supporting Information Appendix S1) was specifically designed for the purpose of data collection and all the team members were instructed by the first author on how to inquire the data consistently and in the same manner. The first part of the questionnaire (seven questions) collected the demographic data and also some confirmatory data (e.g., date of admission, underlying disorders before COVID-19) to cross-check with the primary database. In the second part (20 questions), we asked if the patient has noticed any problems (e.g., self-declared concentration difficulty) or is suffering from any condition during the past week, compared with Missing data: 23

The parƟcipants: 2,696

Died: 1,694

The target populaƟon: 11,471 Every other paƟent (even numbers) were selected: 5,735

The recruitment process of the study their pre-COVID-19 condition (any symptoms or complaints or problems that you did not have before your COVID-19, but have had ever since after your illness and specifically during the past 7 days).

For the purpose of this study, we defined LCS as any symptoms or complaints, or problems that the patients did not have before their COVID-19, but have persistently had for more than 12 weeks (postdischarge) and particularly, during the past 7 days. We specifically asked their complaints during the past 7 days to minimize the risk of recall bias. In the third part of the questionnaire (one question), we asked the patients to compare their "Ability to concentrate and think" with their pre-COVID-19 status based on a Likert scale (1. Much worse; 2. Somewhat worse; 3. The same as before; 4; Somewhat better; 5. Much better). For the purpose of this study, we defined "brain fog" as "concentration difficulty" and a worse status in the "ability to concentrate and think" (both items in Supporting Information Appendix S1 should be declared by the patient for securing an increased accuracy of the collected data since it is a subjective feeling).

The frequency of "brain fog" was reported. Kolmogorov-Smirnov normality test was performed. Values were presented as mean ± standard deviation (SD) or median/interquartile range (IQR) (based on their normality) for continuous variables and as number (percent) of subjects for categorical variables. The following variables were selected as the risk factors potentially associated with "brain fog" in LCS: sex (female: male), age, length of hospital stay, respiratory problems at the onset, neurological problems at the onset, gastrointestinal (GI) problems at the onset, pre-existing chronic medical problems, and ICU admission. Fisher's exact test, t-test (or Kruskal-Wallis test), and binary logistic regression analysis model were used for statistical analyses (significant variables from univariate analyses were entered into the logistic regression analysis model). Odds ratios and 95% confidence intervals were estimated.

A p-value (two-sided) less than 0.05 was considered significant. 3.4 | Factors associated with "brain fog" Table 1 shows factors in association with reporting "brain fog."

Reporting chronic post-COVID "brain fog" was significantly more frequent among women, those with respiratory problems at the onset of infection, and those who had ICU admission, in univariate analyses. We included these three variables in a regression analysis model. The model that was generated by this test was significant (p = 0·0001) and could predict the occurrence of brain fog in 92.8% of the patients. Table 2 shows these factors in association with reporting chronic post-COVID "brain fog." All three factors (i.e., female sex, respiratory problems at the onset of infection, and ICU admission) were significantly associated with reporting chronic post-COVID "brain fog" by the patients.

Publications on long-lasting COVID-19 symptoms, the so-called "long COVID syndrome (LCS)," are increasing very fast, but more should be known about its details and the associated risk factors for various ASADI-POOYA ET AL. | 3 symptoms. 12 In the current study, we observed that 62.3% of the participants reported chronic symptoms/complaints of LCS and 7.2% of these young adults (18-55 years of age) patients with COVID-19 (requiring a hospitalization) had long-lasting complaints of brain fog (inability to think and concentrate). In one study of 384 patients (mean age: 59.9 years; 62% male) followed for a median of 54 days postdischarge, 53% of the patients reported persistent breathlessness and 69% reported fatigue. 13 In a study of 478 patients, 244 patients (51%) declared at least one symptom that did not exist before COVID-19: fatigue was reported by 31% and cognitive symptoms by 21%. 14 In a small study of 29 patients, the authors investigated the frequency and severity of cognitive impairments 3-4 months after COVID-19 hospital discharge with two cognition test batteries (screen for cognitive impairment in psychiatry danish version and the trail making test-part B). 15 The percentage of patients with cognitive impairment was more than 59%. 15 In another study of 4182 patients with COVID-19, individuals self-reported their symptoms prospectively in the COVID-symptom study application. A total of 558 (13.3%) participants reported symptoms lasting ≥28 days. 12 The difference in the methodology may explain the different rates of LCS reported by these studies; while active inquiry suggests a prevalence of more than 50% (observed in our study and the reports by Mandal et al. 13 Morin et al. 14 ) , passive inquiry suggests a much lower prevalence of LCS. It is likely that in the passive inquiry of the symptoms in the study by Sudre et al. 12 people with no LCS (e.g., with no fatigue or brain fog) more frequently used the designed app to participate. Furthermore, the application of cognition test batteries provides higher percentages of cognitive impairments than that by self-declaration by the patients. It is noteworthy to mention that persistent COVID-19-associated neurocognitive symptoms have also been reported by nonhospitalized patients. 16 Cognitive impairment is associated with lower work function and poorer quality of life in the affected people. 15 Therefore, it should be acknowledged more robustly by the scientific community. Screening of all patients, who have recovered from COVID-19, for early detection of any cognitive impairment should be considered and the cost-effectiveness of such a strategy should be investigated in future studies.

In the current study, we observed that female sex, respiratory problems at the onset of infection, and ICU admission were significantly associated with reporting chronic post-COVID "brain fog" by the patients. In a previous study, LCS was more likely in women. 12 In another study of 599 patients, female sex and ICU admission were independent risk factors for the post-COVID-19 syndrome. 17 The reproduced observation that female sex is more often associated with LCS, in general, and brain fog, in particular, is intriguing and should be further explored in future studies. Analysis of the pathophysiological drivers underlying the female sex as a risk factor for LCS is a critical next step. Our observation that ICU admission was significantly associated with experiencing chronic post-COVID "brain fog" and the observations by Peghin et al. 17 that ICU admission was associated with LCS may suggest that a more severe COVID-19 at presentation is a significant risk factor for experiencing LCS, in general, and brain fog in particular. Speculatively, we can hypothesize that a more severe COVID-19 is a risk factor for LCS (including brain fog) because of the following possibilities: 1. Severe COVID-19 is associated with a more severe immune response and cytokine storm, and, consequently, more organ damage (e.g., brain damage) 18-20 ; 2. Severe COVID-19 is usually more aggressively treated and is more often associated with iatrogenic harm (e.g., due to intubation or nosocomial infections) with long-lasting sequelae; 3. Alterations in brain T A B L E 1 Factors in association with reporting "brain fog" in univariate analysis 

A major limitation of this manuscript is that the study is entirely based on phone consultations, with no clinical, psychological, or biological evaluations. In addition, the data on brain fog were not collected prospectively and we cannot provide the information on the temporal relationship (start date) with COVID-19 and brain fog based on the current study. Also, we did not investigate those with a mild illness and asymptomatic infections. Furthermore, if we had included additional questions and if we had not limited the study to the past 7 days, the incidence of brain fog could have been different.

Finally, our findings are limited by the absence of a control group and of pre-COVID assessments in this cohort.

In this large study, we report that chronic post-COVID "brain fog" has significant associations with sex (female), respiratory symptoms at the onset, and the severity of the illness (ICU admission). The scientific community should investigate the pathophysiology of this condition to discover the biological underpinnings of LCS. Ashrafi, Masoume Nazeri, and Sara Nasiri: Data curation, investigation, methodology, project administration, validation, visualization, and writingreview and editing. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

The data are confidential and will not be shared as per the regulations of Shiraz University of Medical Sciences.

Ali A. Asadi-Pooya http://orcid.org/0000-0002-2598-7601

A clinical primer for the expected and potential post-COVID-19 syndromes

Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort

Long COVID-19: Challenges in the diagnosis and proposed diagnostic criteria

Central nervous system manifestations of COVID-19: a systematic review

The landscape of cognitive function in recovered COVID-19 patients

Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex

Long-COVID syndrome? A study on the persistence of neurological, psychological and physiological symptoms

Attributes and predictors of long COVID

Long-COVID": a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables

Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients

Post-COVID-19 symptoms 6 months after acute infection among hospitalized and nonhospitalized patients

Post-COVID-19 symptom burden: what is long-COVID and how should we manage it?

18F-FDG brain PET hypometabolism in patients with long COVID

Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics

Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce "brain fog" and results in behavioral changes that favor viral survival

Long COVID and the role of physical activity: a qualitative study

A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications

Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue

Be aware of SARS-CoV-2 spike protein: there is more than meets the eye

Long COVID syndrome-associated brain fog